The potential of ME1 in guiding immunotherapeutic strategies for ovarian cancer: insights from pan-cancer research
ME1, a metabolic-related factor, has the potential to serve as a biomarker for tumor progression and immune infiltration, particularly in ovarian cancer. It may signify a metabolic reprogramming that supplies energy for tumor progression and immunotherapy, offering valuable insights for the development of personalized therapies.
Authors
- Yumei Wu (ORCID: https://orcid.org/0000-0002-4828-8408)
- Ming Wang
- Jiahui Wei
- Shuiqing Xu
- Paizigul Tusufuhan
Institutions
- Capital Medical University (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Beijing Obstetrics and Gynecology Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1571842
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00